101 related articles for article (PubMed ID: 25449073)
21. De novo acute myeloid leukemia with 20-29% blasts is less aggressive than acute myeloid leukemia with ≥30% blasts in older adults: a Bone Marrow Pathology Group study.
Hasserjian RP; Campigotto F; Klepeis V; Fu B; Wang SA; Bueso-Ramos C; Cascio MJ; Rogers HJ; Hsi ED; Soderquist C; Bagg A; Yan J; Ochs R; Orazi A; Moore F; Mahmoud A; George TI; Foucar K; Odem J; Booth C; Morice W; DeAngelo DJ; Steensma D; Stone RM; Neuberg D; Arber DA
Am J Hematol; 2014 Nov; 89(11):E193-9. PubMed ID: 25042343
[TBL] [Abstract][Full Text] [Related]
22. [A study of NPM1 and FLT3 gene mutations in acute myeloid leukemia].
Wu DP; Yan LZ; Yang L; Chen SN; Wu XJ; Liang JY
Zhonghua Nei Ke Za Zhi; 2007 Nov; 46(11):907-10. PubMed ID: 18261272
[TBL] [Abstract][Full Text] [Related]
23. Down-regulation of pseudogene Vimentin 2p is associated with poor outcome in de novo acute myeloid leukemia.
Zhai LL; Zhou J; Zhang J; Tang X; Zhou LY; Yin JY; Vanessa MD; Peng W; Lin J; Deng ZQ
Cancer Biomark; 2017; 18(3):305-312. PubMed ID: 28106537
[TBL] [Abstract][Full Text] [Related]
24. Prognostic impact of DNMT3A mutations in patients with intermediate cytogenetic risk profile acute myeloid leukemia.
Marková J; Michková P; Burčková K; Březinová J; Michalová K; Dohnalová A; Maaloufová JS; Soukup P; Vítek A; Cetkovský P; Schwarz J
Eur J Haematol; 2012 Feb; 88(2):128-35. PubMed ID: 21967546
[TBL] [Abstract][Full Text] [Related]
25. Down-regulation of GPX3 is associated with favorable/intermediate karyotypes in de novo acute myeloid leukemia.
Zhou JD; Wen XM; Zhang YY; Yang L; Ma YJ; Ma JC; Yang J; Guo H; Yao DM; Lin J; Qian J
Int J Clin Exp Pathol; 2015; 8(3):2384-91. PubMed ID: 26045745
[TBL] [Abstract][Full Text] [Related]
26. Importance of early detection and follow-up of FLT3 mutations in patients with acute myeloid leukemia.
Colovic N; Tosic N; Aveic S; Djuric M; Milic N; Bumbasirevic V; Colovic M; Pavlovic S
Ann Hematol; 2007 Oct; 86(10):741-7. PubMed ID: 17579862
[TBL] [Abstract][Full Text] [Related]
27. Overexpression of Bcl2 protein predicts chemoresistance in acute myeloid leukemia: its correlation with FLT3.
Mehta SV; Shukla SN; Vora HH
Neoplasma; 2013; 60(6):666-75. PubMed ID: 23906301
[TBL] [Abstract][Full Text] [Related]
28. Clinical impact of nucleophosmin mutations and Flt3 internal tandem duplications in patients older than 60 yr with acute myeloid leukaemia.
Scholl S; Theuer C; Scheble V; Kunert C; Heller A; Mügge LO; Fricke HJ; Höffken K; Wedding U
Eur J Haematol; 2008 Mar; 80(3):208-15. PubMed ID: 18081718
[TBL] [Abstract][Full Text] [Related]
29. [CEBPA gene mutation analysis in acute myeloid leukemia].
Han C; Lin D; Ai XF; Wang F; Sun HY; Wang M; Mi YC; Wang JX; Ru K
Zhonghua Xue Ye Xue Za Zhi; 2013 Jul; 34(7):566-71. PubMed ID: 23906447
[TBL] [Abstract][Full Text] [Related]
30. Low SOX17 expression: prognostic significance in de novo acute myeloid leukemia with normal cytogenetics.
Tang CY; Lin J; Qian W; Yang J; Ma JC; Deng ZQ; Yang L; An C; Wen XM; Zhang YY; Qian J
Clin Chem Lab Med; 2014 Dec; 52(12):1843-50. PubMed ID: 24955525
[TBL] [Abstract][Full Text] [Related]
31. Overexpressed let-7a-3 is associated with poor outcome in acute myeloid leukemia.
Li Y; Lin J; Yang J; Qian J; Qian W; Yao DM; Deng ZQ; Liu Q; Chen XX; Xie D; An C; Tang CY
Leuk Res; 2013 Dec; 37(12):1642-7. PubMed ID: 24138945
[TBL] [Abstract][Full Text] [Related]
32. [Flt-3/ITD mutation in pediatric leukemia and its clinical significance].
Wang J; Wang T; Li S; Lin L; Gang Y
Ai Zheng; 2007 Jan; 26(1):58-63. PubMed ID: 17222369
[TBL] [Abstract][Full Text] [Related]
33. CD34 expression on bone marrow blasts is a novel predictor of poor prognosis independent of FlT3-ITD in acute myeloid leukemia with the NPM1-mutation.
Zhu HH; Liu YR; Jiang H; Lu J; Qin YZ; Jiang Q; Bao L; Ruan GR; Jiang B; Huang X
Leuk Res; 2013 Jun; 37(6):624-30. PubMed ID: 23473998
[TBL] [Abstract][Full Text] [Related]
34. Haematological & molecular profile of acute myelogenous leukaemia in India.
Sazawal S; Kumar B; Hasan SK; Dutta P; Kumar R; Chaubey R; Mir R; Saxena R
Indian J Med Res; 2009 Mar; 129(3):256-61. PubMed ID: 19491417
[TBL] [Abstract][Full Text] [Related]
35. Clinical, molecular, and prognostic significance of WHO type inv(3)(q21q26.2)/t(3;3)(q21;q26.2) and various other 3q abnormalities in acute myeloid leukemia.
Lugthart S; Gröschel S; Beverloo HB; Kayser S; Valk PJ; van Zelderen-Bhola SL; Jan Ossenkoppele G; Vellenga E; van den Berg-de Ruiter E; Schanz U; Verhoef G; Vandenberghe P; Ferrant A; Köhne CH; Pfreundschuh M; Horst HA; Koller E; von Lilienfeld-Toal M; Bentz M; Ganser A; Schlegelberger B; Jotterand M; Krauter J; Pabst T; Theobald M; Schlenk RF; Delwel R; Döhner K; Löwenberg B; Döhner H
J Clin Oncol; 2010 Aug; 28(24):3890-8. PubMed ID: 20660833
[TBL] [Abstract][Full Text] [Related]
36. Absence of the wild-type allele predicts poor prognosis in adult de novo acute myeloid leukemia with normal cytogenetics and the internal tandem duplication of FLT3: a cancer and leukemia group B study.
Whitman SP; Archer KJ; Feng L; Baldus C; Becknell B; Carlson BD; Carroll AJ; Mrózek K; Vardiman JW; George SL; Kolitz JE; Larson RA; Bloomfield CD; Caligiuri MA
Cancer Res; 2001 Oct; 61(19):7233-9. PubMed ID: 11585760
[TBL] [Abstract][Full Text] [Related]
37. Mutant FLT3: a direct target of sorafenib in acute myelogenous leukemia.
Zhang W; Konopleva M; Shi YX; McQueen T; Harris D; Ling X; Estrov Z; Quintás-Cardama A; Small D; Cortes J; Andreeff M
J Natl Cancer Inst; 2008 Feb; 100(3):184-98. PubMed ID: 18230792
[TBL] [Abstract][Full Text] [Related]
38. Detailed analysis of FLT3 expression levels in acute myeloid leukemia.
Kuchenbauer F; Kern W; Schoch C; Kohlmann A; Hiddemann W; Haferlach T; Schnittger S
Haematologica; 2005 Dec; 90(12):1617-25. PubMed ID: 16330434
[TBL] [Abstract][Full Text] [Related]
39. CDH1 (E-cadherin) expression independently affects clinical outcome in acute myeloid leukemia with normal cytogenetics.
Zhang TJ; Zhou JD; Ma JC; Deng ZQ; Qian Z; Yao DM; Yang J; Li XX; Lin J; Qian J
Clin Chem Lab Med; 2017 Jan; 55(1):123-131. PubMed ID: 27305704
[TBL] [Abstract][Full Text] [Related]
40. Musashi2 modulates K562 leukemic cell proliferation and apoptosis involving the MAPK pathway.
Zhang H; Tan S; Wang J; Chen S; Quan J; Xian J; Zhang Ss; He J; Zhang L
Exp Cell Res; 2014 Jan; 320(1):119-27. PubMed ID: 24076374
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
